New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Prelude Therapeutics Incorporated (PRLD) vs SAB Biotherapeutics, Inc. (SABS)
- Prelude Therapeutics Incorporated PRLD 3.23 −0.92%
- SAB Biotherapeutics, Inc. SABS 2.81 −3.44%
Prelude Therapeutics Incorporated and SAB Biotherapeutics, Inc. are both Biotechnology companies. Prelude Therapeutics Incorporated and SAB Biotherapeutics, Inc. are of similar size ($262.2M and $260.5M). Prelude Therapeutics Incorporated has the higher net margin (−247.1% vs −1,450.3%) and the higher return on invested capital (0.00% vs −48.4%). Across the 15 metrics below, Prelude Therapeutics Incorporated leads on 11 and SAB Biotherapeutics, Inc. on 4.
Valuation
Profitability
| Metric | PRLD | SABS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 70.18% |
| Operating margin | (283.92%) | (1,647.03%) | 0.00% |
| Net margin | (247.12%) | (1,450.32%) | 0.00% |
| Free cash flow margin | (129.68%) | (1,344.29%) | 0.00% |
| Return on equity | (58.36%) | (47.62%) | (51.58%) |
| Return on assets | (39.45%) | (42.73%) | (45.91%) |
| Return on invested capital | 0.00% | (48.38%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack